Want to see HK:6872 full AI Analyst Report?
Total Valuation
TenNor Therapeutics Suzhou Ltd. Class H has a market cap or net worth of HK$5.87B. The enterprise value is $10.69B.
Market CapHK$5.87B
Enterprise Value$10.69B
Share Statistics
TenNor Therapeutics Suzhou Ltd. Class H has 52,328,926 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,328,926
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
TenNor Therapeutics Suzhou Ltd. Class H’s return on equity (ROE) is -1.00 and return on invested capital (ROIC) is -57.19%.
Return on Equity (ROE)-1.00
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-57.19%
Return on Capital Employed (ROCE)-0.63
Revenue Per Employee0.00
Profits Per Employee-2.74M
Employee Count56
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of TenNor Therapeutics Suzhou Ltd. Class H is ―. TenNor Therapeutics Suzhou Ltd. Class H’s PEG ratio is -12.90.
PE Ratio―
PS Ratio0.00
PB Ratio63.75
Price to Fair Value63.75
Price to FCF-111.91
Price to Operating Cash Flow0.00
PEG Ratio-12.90
Income Statement
In the last 12 months, TenNor Therapeutics Suzhou Ltd. Class H had revenue of 0.00 and earned -153.24M in profits. Earnings per share was -2.96.
Revenue0.00
Gross Profit0.00
Operating Income-118.67M
Pretax Income-153.24M
Net Income-153.24M
EBITDA-150.18M
Earnings Per Share (EPS)-2.96
Cash Flow
In the last 12 months, operating cash flow was -33.14M and capital expenditures -74.85K, giving a free cash flow of -33.21M billion.
Operating Cash Flow-33.14M
Free Cash Flow-33.21M
Free Cash Flow per Share-0.63
Dividends & Yields
TenNor Therapeutics Suzhou Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.06
52-Week Price Change-46.87%
50-Day Moving Average163.40
200-Day Moving Average―
Relative Strength Index (RSI)26.99
Average Volume (3m)124.85K
Important Dates
TenNor Therapeutics Suzhou Ltd. Class H upcoming earnings date is Aug 26, 2026, Before Open (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateAug 26, 2026
Ex-Dividend Date―
Financial Position
TenNor Therapeutics Suzhou Ltd. Class H as a current ratio of 5.02, with Debt / Equity ratio of 18.62%
Current Ratio5.02
Quick Ratio5.02
Debt to Market Cap<0.01
Net Debt to EBITDA1.03
Interest Coverage Ratio-80.07
Taxes
In the past 12 months, TenNor Therapeutics Suzhou Ltd. Class H has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
TenNor Therapeutics Suzhou Ltd. Class H EV to EBITDA ratio is -64.28, with an EV/FCF ratio of -110.14.
EV to Sales0.00
EV to EBITDA-64.28
EV to Free Cash Flow-110.14
EV to Operating Cash Flow-110.71
Balance Sheet
TenNor Therapeutics Suzhou Ltd. Class H has HK$183.76M in cash and marketable securities with HK$28.65M in debt, giving a net cash position of HK$155.11M billion.
Cash & Marketable SecuritiesHK$183.76M
Total DebtHK$28.65M
Net CashHK$155.11M
Net Cash Per ShareHK$2.96
Tangible Book Value Per ShareHK$2.48
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for TenNor Therapeutics Suzhou Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―